Please login to the form below

Not currently logged in
Email:
Password:

BMS names chairman of the board

Giovanni Caforio to succeed Lamberto Andreotti on 2 May

BMS Giovanni CaforioBristol-Myers Squibb has selected its chief executive officer Giovanni Caforio to succeed Lamberto Andreotti as chairman of its board of directors from 2 May this year.

Caforio first joined BMS in 2000 as vice president and general manager of the company's operations in Italy, before taking on increasingly senior European positions.

He became senior vice president of global oncology and immunology in 2011, and was promoted to BMS' president of US pharmaceuticals later that year.

More recently, Caforio became an executive vice president and served as chief commercial officer and chief operating officer from 2013 and 2014, respectively.

Andreotti said: “Since being named chief executive officer, Giovanni has clearly demonstrated the capabilities needed to lead Bristol-Myers Squibb in the near and long term.

“It was a pleasure working with Giovanni during this transition period, and I have full confidence that he will do what is needed to continue to deliver on the company's mission and generate sustainable growth for our shareholders now and in the future.”

10th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

OUTiCO Case Study - Product Launch
POSITIVE FORMULARY SUCCESS WITHIN 8 MONTHS!...
An insight into Multi-Channel Account Management
At OUTiCO we often talk about moving away from traditional methods, embracing change, and offering an exceptional outsourcing service, but what does that mean day to day?...
14_ipad_lowres.jpg
Why AI might be the rep’s best friend
When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...

Infographics